MétaCan
Menu
← Back to cohort
Record W4409629189 · doi:10.1158/1538-7445.am2025-4289

Abstract 4289: Discovery of potent RAD51 inhibitors with anticancer activity in preclinical models of non-small cell lung cancer

2025· article· en· W4409629189 on OpenAlexaff
Yifan Yu, Morgan Black, Nikolina Radulovich, Peter Ferguson, James Koropatnick, Ming‐Sound Tsao, Mark Vincent, Geoffrey Liu, Samir H. Barghout

Bibliographic record

VenueCancer Research · 2025
Typearticle
Languageen
FieldMedicine
TopicLung Cancer Treatments and Mutations
Canadian institutionsWestern UniversityUniversity Health Network
Fundersnot available
KeywordsCancerMedicineLung cancerPharmacologyCancer researchComputational biologyOncologyBiologyInternal medicine

Abstract

fetched live from OpenAlex

RAD51 is a protein that plays a key, canonical role in double-strand break (DSB) repair through homologous recombination (HR) and is biologically important for maintaining genome stability. Given its additional, non-canonical role in mitigating the replication stress characteristic of tumor cells, RAD51 has emerged as an attractive therapeutic target in several malignancies including non-small cell lung cancer (NSCLC). Nonetheless, drug discovery endeavors for developing direct RAD51 inhibitors have had limited success. Here, we describe a series of novel RAD51 inhibitors and their cytotoxic activity in preclinical models of NSCLC. We accessed and improved upon a previously discovered series of phenylsulfonyl indolyl isoquinoline derivatives that bind to the hydrophobic pocket of RAD51 preventing its multimerization and interaction with BRCA2. Of these, JKYN-1 and its mesylate salt (patent application # CA3204011A1) displayed potent and selective RAD51 inhibition in cell-free assays. Given the biological importance of replication stress in a subset of NSCLC, we assessed the cytotoxicity of these RAD51 inhibitors in preclinical models of NSCLC. Using the CellTiter-Glo assay, JKYN-1 displayed cytotoxicity in A549 and H1975 cell lines with lower IC50 values compared to the classical RAD51 inhibitor B02 (A549, 4.9 vs >10 μM; H1975, 3.2 vs 8.3 μM). We subsequently assessed the cytotoxicity in a panel of 7 patient-derived organoids (PDOs) of NSCLC with diverse molecular, genetic, and clinical profiles (LPTO308, XDO137, LPTO357, LPTO318, LPTO366, LPTO362, LPTO221). In these models, JKYN-1 and JKYN-1-mesylate displayed a highly potent cytotoxicity with sub-micromolar IC50 values between 0.1-0.87 μM as opposed to B02 that had IC50 values between 3.7 to >10 μM. In conclusion, our data identify JKYN-1 and its mesylate salt as potent and selective RAD51 inhibitors with superior cytotoxic activity compared to classical inhibitors such as B02. These findings highlight the potential of these novel compounds as promising therapeutic agents in a subset of NSCLC. Citation Format: Yifan Yu, Morgan Black, Nikolina Radulovich, Peter Ferguson, James Koropatnick, Ming Tsao, Mark D. Vincent, Geoffrey Liu, Samir H. Barghout. Discovery of potent RAD51 inhibitors with anticancer activity in preclinical models of non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 4289.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.009

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.066
GPT teacher head0.463
Teacher spread0.397 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueCancer Research→Same topicLung Cancer Treatments and Mutations→French-language works237,207→